Loading data for TRAW — first visit, this takes a few seconds.
Traws Pharma, Inc.
0.52 +0.00 (0.00%)
- Ринкова капіталізація
- $8.04M
- Обсяг торгів
- 3.72K
- Наступна дата звітності
- Aug 14, 2025
Traws Pharma, Inc. (TRAW): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $0 | n/a | -100.00% |
| EPS | -$0,18 | +$0,27 | +97.96% |
Показники
- Купівля
- 0.36
- Ринкова капіталізація
- 8.04M
- Чистий прибуток (ttm)
- -16.4M
- 1.60
- -1.83
- n/a
- -0.28
- P/B (ttm)
- 4.72
- P/S (ttm)
- n/a
- Дата звіту
- Aug 14, 2025
- Продаж
- 0.71
- Обсяг торгів
- 3,720
- Сер. обсяг (20 дн.)
- 151,582
- Відкриття
- 0.52
- Попереднє закриття
- 0.52
- Діапазон дня
- 0.52 - 0.52
- Діапазон за 52 тижні
- 0.43 - 3.27
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- n/a
Про Traws Pharma, Inc.
Профіль →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.